Celldex Therapeutics reported $456.23M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 538M Mar/2026
Agenus USD -221.22M 241.03M Mar/2026
Amgen USD 4.78B 1.12B Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Celldex Therapeutics USD 456.23M 368.95M Mar/2026
Glaxosmithkline GBP 9.17B 1.4B Dec/2025
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Northwest Biotherapeutics USD -108.65M 8.26M Sep/2025
Pfizer USD 90.1B 77.19B Mar/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Roche Holding CHF 21.01B 10.84B Dec/2025